Some people are splurging. Others are finding that their refunds are being swallowed up by the rising cost of gas.

Capping Medicare beneficiaries’ monthly insulin out-of-pocket costs at $35 was associated with steep reductions in spending and modest but meaningful improvements in glycemic control —yet did little to draw new patients onto insulin therapy. The cap was initially introduced for some beneficiaries before expanding to all beneficiaries.

The very spending that has some investors clutching their portfolios turns out to be the smartest infrastructure bet since the original cloud build-out. In today’s AI-driven economy, hyperscalers are racing to wire the future.